Q-omics provides the consensus-scored TCEANC profile across patient tissues and cancer cell-line models. TCEANC expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCEANC is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, TCEANC RNA expression shows 20,328 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TCEANC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEANC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEANC survival associations across molecular data types. TCEANC RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEANC RNA expression–survival associations across cancer types. High TCEANC expression shows favorable associations in KIRC, PAAD, ACC, HNSC, BLCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCEANC RNA expression.
This table summarizes TCEANC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TCEANC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEANC shows lower tumor expression in THCA, KICH, LUAD and LUSC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher TCEANC RNA expression in normal versus tumor tissue (log2 FC = −1.167, t-test p < 0.001).
This table shows molecular features associated with TCEANC in patient tissues and cancer cell lines. In patient samples, TCEANC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEANC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
